查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太地區伴同性診斷市場：按技術、按應用、按最終用戶、按國家 - 分析和預測（2023-2033年）
市場調查報告書
商品編碼
1585128

亞太地區伴同性診斷市場：按技術、按應用、按最終用戶、按國家 - 分析和預測（2023-2033年）

Asia-Pacific Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 73 Pages | 商品交期: 1-5個工作天內

價格

2023年，亞太地區伴同性診斷市場價值為 7.337億美元。

預計2023年至2033年該市場將以14.53%的年複合成長率成長，2033年達到28.497億美元。由於伴同性診斷工具的核准不斷增加、生物醫學影像的改進以及癌症發病率的上升，亞太地區伴同性診斷市場不斷成長。這些是亞太地區在個人化癌症護理中擴大使用精準醫療和伴同性診斷的關鍵促進因素。

主要市場統計資料
預測期 2023-2033
2023年評估 7.337億美元
2033年預測 28.497億美元
年複合成長率 14.53%

由於對個人化治療的需求不斷成長以及慢性病（尤其是癌症）的盛行率上升，亞太地區的伴同性診斷市場預計將出現顯著發展。為了提供更專業、更有效的治療選擇，伴同性診斷是幫助識別最有可能從特定藥物中受益的患者的重要工具。隨著該地區癌症發病率的增加以及對精準治療的關注的增加，伴同性診斷變得越來越重要。

此外，檢測開發和生物標記發現的技術發展也在推動市場。基因組和分子測試技術的進步導致與各種疾病相關的生物標記的發現，使得開發客製化治療方法變得更加容易。此外，鼓勵性的法律體制、製藥公司增加研發資金也有助於市場擴張。

引進伴同性診斷的主要企業是中國、印度和日本，這些國家的生物製藥公司和診斷公司之間有許多合作。隨著患者和醫療保健專業人員越來越意識到個人化醫療的好處，亞太地區伴同性診斷市場預計將擴大，為醫療保健生態系統中的所有相關人員提供巨大的潛力。

本報告研究了亞太地區伴同性診斷市場，並提供了市場概述，包括依技術、應用、最終用戶、國家/地區分類的趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章 市場

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研究發展回顧
  • 監管狀況
  • 從歷史角度進行伴同性診斷
  • 伴同性診斷（CDx）開發的組成部分
  • 伴同性診斷（CDx）：未來的可能性
  • 市場動態概覽

第2章 區域

  • 區域概況
  • 促進因素和抑制因素
  • 亞太地區

第3章 市場－競爭基準化分析與公司概況

  • 未來展望
  • 地理評估
    • Amoy Diagnostics Co., Ltd.
    • Novogene Co, Ltd.
    • Sysmex Corporation

第4章 調查方法

Product Code: BHP2385SS

Introduction to Asia-Pacific Companion Diagnostics Market

The Asia-Pacific companion diagnostics market was valued at $733.7 million in 2023 and is expected to reach $2,849.7 million by 2033, growing at a CAGR of 14.53% between 2023 and 2033. The Asia-Pacific (APAC) companion diagnostics market is growing as a result of increased approvals for companion diagnostic tools, improvements in biomedical imaging, and the rising incidence of cancer. These are the main causes of the increasing use of precision medicine and companion diagnostics in APAC's individualized cancer treatment.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$733.7 Million
2033 Forecast$2,849.7 Million
CAGR14.53%

The market for companion diagnostics in Asia-Pacific (APAC) is expected to develop significantly due to the increased need for personalized therapy and the rising prevalence of chronic diseases, especially cancer. In order to provide more specialized and efficient treatment options, companion diagnostics are crucial instruments that assist in identifying patients who are most likely to benefit from particular medicines. Companion diagnostics are becoming more and more important as the region sees an increase in cancer incidence and a greater focus on precision treatment.

The market is also being driven ahead by technological developments in assay development and biomarker discovery. The development of customized treatments is made easier by the discovery of biomarkers linked to a variety of diseases thanks to advancements in genomic and molecular testing technology. Furthermore, encouraging legal frameworks, more funding for research and development by pharmaceutical companies are contributing to the market's expansion.

Leading the way in the adoption of companion diagnostics are nations like China, India, and Japan, where biopharmaceutical businesses and diagnostic companies have partnered in large numbers. The APAC companion diagnostic market is expected to increase as patients and healthcare professionals become more aware of the advantages of personalized medicine, providing substantial potential for all parties involved in the healthcare ecosystem.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)
  • Others

Segmentation 2: by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Stomach Cancer
  • Melanoma
  • Others

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Reference Laboratories and Hospitals
  • Others

Segmentation 4: by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Amoy Diagnostics Co., Ltd.
  • Novogene Co, Ltd.
  • Sysmex Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Companion Diagnostics Market Trend Analysis
    • 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
    • 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Legal Requirements and Framework by the FDA
    • 1.4.2 Legal Requirements and Framework by the MHLW
  • 1.5 CDx from a Historical Perspective
  • 1.6 Constituents for Companion Diagnostics (CDx) Development
  • 1.7 Companion Diagnostics (CDx): Future Potential
  • 1.8 Market Dynamics Overview
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Cancer Cases
      • 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
      • 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
    • 1.8.2 Market Restraints
      • 1.8.2.1 Uncertain Reimbursement Scenario
      • 1.8.2.2 Stringent Regulatory Approval Processes
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
      • 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

2 Regions

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Asia-Pacific
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 China
    • 2.3.7 Application
    • 2.3.8 Product
    • 2.3.9 India
    • 2.3.10 Application
    • 2.3.11 Product
    • 2.3.12 Australia
    • 2.3.13 Application
    • 2.3.14 Product
    • 2.3.15 Japan
    • 2.3.16 Application
    • 2.3.17 Product
    • 2.3.18 South Korea
    • 2.3.19 Application
    • 2.3.20 Product
    • 2.3.21 Rest-of-Asia-Pacific
    • 2.3.22 Application
    • 2.3.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers.....
  • 3.2 Geographic Assessment
    • 3.2.1 Amoy Diagnostics Co., Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Novogene Co, Ltd.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Sysmex Corporation
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Asia-Pacific Companion Diagnostics Market, $Million, 2023, 2026, and 2033
  • Figure 2: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 4: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
  • Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
  • Figure 7: Applications of Digital Diagnostics
  • Figure 8: Supply Chain and Risks within the Supply Chain
  • Figure 9: Companion Diagnostics Market (by Country), January 2021-December 2023
  • Figure 10: Companion Diagnostics (by Year), January 2021-December 2023
  • Figure 11: Evolution of Companion Diagnostics
  • Figure 12: Components Required to Develop Companion Diagnostics
  • Figure 13: Future Prospects of CDx
  • Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
  • Figure 15: Factors Impacting Reimbursement Scenario
  • Figure 16: Advancements in Companion Diagnostics
  • Figure 17: Future Outlook of Epigenomics
  • Figure 18: Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 19: China Companion Diagnostics Market, $Million, 2022-2033
  • Figure 20: India Companion Diagnostics Market, $Million, 2022-2033
  • Figure 21: Australia Companion Diagnostics Market, $Million, 2022-2033
  • Figure 22: Japan Companion Diagnostics Market, $Million, 2022-2033
  • Figure 23: South Korea Companion Diagnostics Market, $Million, 2022-2033
  • Figure 24: Rest-of-Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 25: Strategic Initiatives, 2021-2023
  • Figure 26: Share of Strategic Initiatives, 2021-2023
  • Figure 27: Data Triangulation
  • Figure 28: Top-Down and Bottom-Up Approach
  • Figure 29: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Companion Diagnostics Market, Opportunities
  • Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
  • Table 4: Cancer Cases Expected between 2020 and 2040
  • Table 5: Product Approvals in the Field of Companion Diagnostics
  • Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
  • Table 7: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 8: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 9: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 10: China Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 11: China Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 12: China Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 13: India Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 14: India Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 15: India Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 16: Australia Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 17: Australia Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 18: Australia Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 19: Japan Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 20: Japan Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 21: Japan Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 22: South Korea Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 23: South Korea Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 24: South Korea Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 25: Rest-of-Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 26: Rest-of-Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 27: Rest-of-Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033